Pharmafile Logo

News and Press Releases

European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD  

· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma  · First Significant Improvement in Overall Survival in Two Decades...

Category: Pharmaceutical
Posted: October 23, 2023

Takeda Pharmaceutical Company
61 Aldwych, London, WC2B 4AE, UK

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oral presentation highlights new findings about the efficacy of XACDURO for the treatment of monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus infections Researchers share global surveillance data on the in vitro activity of XERAVA (eravacycline) for injection on...

Category: Pharmaceutical
Posted: October 12, 2023

Innoviva
info@istx.com
Boston BioHub 35 Gatehouse Drive Waltham, MA USA 02451

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...

Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

MODERNA RECEIVES US FDA APPROVAL FOR UPDATED COVID-19 VACCINE

Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86 Updated vaccine to be available in pharmacies and care settings across the US in the...

Category: Clinical Trials
Posted: September 12, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

MODERNA CLINICAL TRIAL DATA CONFIRMS ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS 

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant  Updated vaccine expected to be available, pending approval, in coming weeks...

Category: Other
Posted: August 22, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139